FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334172378> ?p ?o ?g. }

• W2334172378 abstract "Induced differentiation of malignant cells presents a treatment alternative less toxic than the conventional therapeutic approaches. In particular, Acute Myeloid Leukemia (AML) cells have been shown to differentiate along the monocytic lineage when treated with the active form of vitamin D3 (1,25D), and along the granulocytic lineage after exposure to all-trans retinoic acid (ATRA). While induced differentiation of human AML cells is associated with cell cycle blocks and cessation of cell proliferation, whether treated with 1,25D or ATRA, 1,25D-induced monocytic differentiation is accompanied by somewhat increased cell survival during drug-elicited cellular stress, which counters the therapeutic objective of malignant cell elimination. In contrast, granulocytic differentiation leads to cell death, suggesting that this is the preferred mode of differentiation in a therapeutic setting. In the current study we have observed that inhibition of the MEK5/ERK5 MAPK pathway in 1,25D-treated human AML cells switches the phenotype from monocytic to granulocytic, as evidenced by decreased expression of monocytic markers CD14 and Monocyte Specific Esterase (MSE), concurrent with an increase in general myeloid/granulocytic markers CD11b and CD11c, as well as NBT positivity. On the molecular level, the switch from the monocytic to granulocytic phenotype was accompanied by reduced levels of phosphorylation of transcription factor (TF) C/EBPb but increased phosphorylation of C/EBPa. The requirement for activated ERK5 in monocytic differentiation was also shown by the use of Bix 02189, a specific inhibitor of MEK5 kinase activity, and by the transfection of siRNA to ERK5. Inhibition of ERK1/2 activity by PD098059 reduced monocytic differentiation, but did not alter the 1,25D-induced monocytic phenotype, showing that ERK1/2 and ERK5 serve different functions in differentiation signaling. Importantly, ERK5 appears to control the activation of the TF c-jun/AP1, previously shown to be required for 1, 25D- induced monocytic differentiation, and of the TF MEF2C, not previously linked to 1,25D action or to monocytic differentiation. Thus, our results suggest that ERK5 inhibitors should be evaluated as potentiators of the therapeutic effects of vitamin D analogs in the proposed clinical trials of AML therapy, and raise the possibility that ERK5 inhibitors may also augment the granulocytic differentiation induced by ATRA in the treatment of APL. (Supported by the NIH grant R01-CA-077422-22 from the National Cancer Institute). Citation Format: Xuening Wang, Ajay Menon, Elzbieta Gocek, Michael Danilenko, Jonathan S. Harrison, George P. Studzinski. Inhibition of the MEK5/ERK5 pathway can redirect 1,25-dihydroxyvitamin D3-treated human AML cells from monocytic to granulocytic lineage of differentiation. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5451. doi:10.1158/1538-7445.AM2013-5451" @default.
• W2334172378 created "2016-06-24" @default.
• W2334172378 creator A5015147430 @default.
• W2334172378 creator A5023251160 @default.
• W2334172378 creator A5029065397 @default.
• W2334172378 creator A5046738148 @default.
• W2334172378 creator A5067073141 @default.
• W2334172378 creator A5086633044 @default.
• W2334172378 date "2013-04-15" @default.
• W2334172378 modified "2023-09-27" @default.
• W2334172378 title "Abstract 5451: Inhibition of the MEK5/ERK5 pathway can redirect 1,25-dihydroxyvitamin D3-treated human AML cells from monocytic to granulocytic lineage of differentiation." @default.
• W2334172378 doi "https://doi.org/10.1158/1538-7445.am2013-5451" @default.
• W2334172378 hasPublicationYear "2013" @default.
• W2334172378 type Work @default.
• W2334172378 sameAs 2334172378 @default.
• W2334172378 citedByCount "0" @default.
• W2334172378 crossrefType "proceedings-article" @default.
• W2334172378 hasAuthorship W2334172378A5015147430 @default.
• W2334172378 hasAuthorship W2334172378A5023251160 @default.
• W2334172378 hasAuthorship W2334172378A5029065397 @default.
• W2334172378 hasAuthorship W2334172378A5046738148 @default.
• W2334172378 hasAuthorship W2334172378A5067073141 @default.
• W2334172378 hasAuthorship W2334172378A5086633044 @default.
• W2334172378 hasConcept C104317684 @default.
• W2334172378 hasConcept C127716648 @default.
• W2334172378 hasConcept C148738053 @default.
• W2334172378 hasConcept C203014093 @default.
• W2334172378 hasConcept C2776601000 @default.
• W2334172378 hasConcept C2778513237 @default.
• W2334172378 hasConcept C2778729363 @default.
• W2334172378 hasConcept C2779282312 @default.
• W2334172378 hasConcept C2779919695 @default.
• W2334172378 hasConcept C2779963572 @default.
• W2334172378 hasConcept C2779982571 @default.
• W2334172378 hasConcept C2781121885 @default.
• W2334172378 hasConcept C2781184567 @default.
• W2334172378 hasConcept C502942594 @default.
• W2334172378 hasConcept C54355233 @default.
• W2334172378 hasConcept C553184892 @default.
• W2334172378 hasConcept C55493867 @default.
• W2334172378 hasConcept C81885089 @default.
• W2334172378 hasConcept C86803240 @default.
• W2334172378 hasConcept C95444343 @default.
• W2334172378 hasConceptScore W2334172378C104317684 @default.
• W2334172378 hasConceptScore W2334172378C127716648 @default.
• W2334172378 hasConceptScore W2334172378C148738053 @default.
• W2334172378 hasConceptScore W2334172378C203014093 @default.
• W2334172378 hasConceptScore W2334172378C2776601000 @default.
• W2334172378 hasConceptScore W2334172378C2778513237 @default.
• W2334172378 hasConceptScore W2334172378C2778729363 @default.
• W2334172378 hasConceptScore W2334172378C2779282312 @default.
• W2334172378 hasConceptScore W2334172378C2779919695 @default.
• W2334172378 hasConceptScore W2334172378C2779963572 @default.
• W2334172378 hasConceptScore W2334172378C2779982571 @default.
• W2334172378 hasConceptScore W2334172378C2781121885 @default.
• W2334172378 hasConceptScore W2334172378C2781184567 @default.
• W2334172378 hasConceptScore W2334172378C502942594 @default.
• W2334172378 hasConceptScore W2334172378C54355233 @default.
• W2334172378 hasConceptScore W2334172378C553184892 @default.
• W2334172378 hasConceptScore W2334172378C55493867 @default.
• W2334172378 hasConceptScore W2334172378C81885089 @default.
• W2334172378 hasConceptScore W2334172378C86803240 @default.
• W2334172378 hasConceptScore W2334172378C95444343 @default.
• W2334172378 hasLocation W23341723781 @default.
• W2334172378 hasOpenAccess W2334172378 @default.
• W2334172378 hasPrimaryLocation W23341723781 @default.
• W2334172378 hasRelatedWork W1978961590 @default.
• W2334172378 hasRelatedWork W1991400890 @default.
• W2334172378 hasRelatedWork W2010973343 @default.
• W2334172378 hasRelatedWork W2022116593 @default.
• W2334172378 hasRelatedWork W2078216903 @default.
• W2334172378 hasRelatedWork W2079483713 @default.
• W2334172378 hasRelatedWork W2092648511 @default.
• W2334172378 hasRelatedWork W2111476141 @default.
• W2334172378 hasRelatedWork W2119925358 @default.
• W2334172378 hasRelatedWork W2124684432 @default.
• W2334172378 hasRelatedWork W2125050173 @default.
• W2334172378 hasRelatedWork W2142945689 @default.
• W2334172378 hasRelatedWork W2414037719 @default.
• W2334172378 hasRelatedWork W2519062730 @default.
• W2334172378 hasRelatedWork W2552184685 @default.
• W2334172378 hasRelatedWork W2556605078 @default.
• W2334172378 hasRelatedWork W257159349 @default.
• W2334172378 hasRelatedWork W2589740359 @default.
• W2334172378 hasRelatedWork W2979962056 @default.
• W2334172378 hasRelatedWork W2993995834 @default.
• W2334172378 isParatext "false" @default.
• W2334172378 isRetracted "false" @default.
• W2334172378 magId "2334172378" @default.
• W2334172378 workType "article" @default.